Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy
Yuqing Cao, Xiaoyu Wang, Tianqiang Jin, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 120

Showing 1-25 of 120 citing articles:

Radiotherapy combined with immunotherapy: the dawn of cancer treatment
Zengfu Zhang, Xu Liu, Dawei Chen, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 351
The Crosstalk Between Tumor Cells and the Immune Microenvironment in Breast Cancer: Implications for Immunotherapy
Vincenzo Salemme, Giorgia Centonze, Federica Cavallo, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 182
Microneedles for painless transdermal immunotherapeutic applications
Hamed Amani, Mohammad‐Ali Shahbazi, Carmine D’Amico, et al.
Journal of Controlled Release (2020) Vol. 330, pp. 185-217
Closed Access | Times Cited: 179
Adaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment
Peijie Wu, Wei Gao, Miao Su, et al.
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 158
Long non-coding RNAs in the doxorubicin resistance of cancer cells
Saeed Ashrafizaveh, Milad Ashrafizadeh, Ali Zarrabi, et al.
Cancer Letters (2021) Vol. 508, pp. 104-114
Open Access | Times Cited: 152
iPSC-Derived Natural Killer Cell Therapies - Expansion and Targeting
Benjamin Goldenson, Pooja Hor, Dan S. Kaufman
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 86
Cancer exosomes and natural killer cells dysfunction: biological roles, clinical significance and implications for immunotherapy
Reza Hosseini, Hamzeh Sarvnaz, Maedeh Arabpour, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 74
Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy
Matin Chehelgerdi, Fereshteh Behdarvand Dehkordi, Mohammad Chehelgerdi, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 66
Effects of Chemotherapy on the Immune System: Implications for Cancer Treatment and Patient Outcomes
Anirudh Sharma, Shivam Jasrotia, Ajay Kumar
Naunyn-Schmiedeberg s Archives of Pharmacology (2023) Vol. 397, Iss. 5, pp. 2551-2566
Closed Access | Times Cited: 42
Therapeutic application of human type 2 innate lymphoid cells via induction of granzyme B-mediated tumor cell death
Zhenlong Li, Rui Ma, Hejun Tang, et al.
Cell (2024) Vol. 187, Iss. 3, pp. 624-641.e23
Closed Access | Times Cited: 28
CAR-NK Cells: From Natural Basis to Design for Kill
Muhammad Babar Khawar, Haibo Sun
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 95
Microfluidics applications for high-throughput single cell sequencing
Wen-min Zhou, Yan-yan Yan, Qiao-ru Guo, et al.
Journal of Nanobiotechnology (2021) Vol. 19, Iss. 1
Open Access | Times Cited: 88
Chimeric Antigen Receptor-Engineered Natural Killer (CAR NK) Cells in Cancer Treatment; Recent Advances and Future Prospects
Reza Elahi, Amir Hossein Heidary, Kaveh Hadiloo, et al.
Stem Cell Reviews and Reports (2021) Vol. 17, Iss. 6, pp. 2081-2106
Open Access | Times Cited: 62
LAG-3 as a Potent Target for Novel Anticancer Therapies of a Wide Range of Tumors
Natalia Sauer, Wojciech Szlasa, Laura Jonderko, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 17, pp. 9958-9958
Open Access | Times Cited: 52
Remodeled tumor immune microenvironment (TIME) parade via natural killer cells reprogramming in breast cancer
Mona M. Elanany, Dina Mostafa, Nadia Μ. Hamdy
Life Sciences (2023) Vol. 330, pp. 121997-121997
Closed Access | Times Cited: 32
NK Cells in Cancer: Mechanisms of Dysfunction and Therapeutic Potential
Federica Portale, Diletta Di Mitri
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 11, pp. 9521-9521
Open Access | Times Cited: 26
Polymer Micropatches as Natural Killer Cell Engagers for Tumor Therapy
Supriya Prakash, Ninad Kumbhojkar, Andrew Lu, et al.
ACS Nano (2023) Vol. 17, Iss. 16, pp. 15918-15930
Closed Access | Times Cited: 24
Therapeutic and immunomodulatory potentials of mesenchymal stromal/stem cells and immune checkpoints related molecules
Ali Hazrati, Kosar Malekpour, Hossein Khorramdelazad, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 11
An emerging strategy: probiotics enhance the effectiveness of tumor immunotherapy via mediating the gut microbiome
Shuaiming Jiang, Wenyao Ma, Chenchen Ma, et al.
Gut Microbes (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 9
The dynamic role of immune checkpoint molecules in diagnosis, prognosis, and treatment of head and neck cancers
S Mestiri, Dina Moustafa Abo El-Ella, Queenie Fernandes, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 171, pp. 116095-116095
Open Access | Times Cited: 8
Targeting natural killer cells: from basic biology to clinical application in hematologic malignancies
Juanjuan Shang, Shunfeng Hu, Xin Wang
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 8
Precise Capture and Dynamic Release of Circulating Liver Cancer Cells with Dual‐Histidine‐Based Cell Imprinted Hydrogels
Wenjing Sun, Xin You, Xinjia Zhao, et al.
Advanced Materials (2024) Vol. 36, Iss. 27
Closed Access | Times Cited: 8
Targeting of the tumor microenvironment by curcumin
Xiao Fu, Yingni He, Mu Li, et al.
BioFactors (2021) Vol. 47, Iss. 6, pp. 914-932
Closed Access | Times Cited: 51
Bi-specific and Tri-specific NK Cell Engagers: The New Avenue of Targeted NK Cell Immunotherapy
Shee Kwan Phung, Jeffrey S. Miller, Martin Felices
Molecular Diagnosis & Therapy (2021) Vol. 25, Iss. 5, pp. 577-592
Closed Access | Times Cited: 47
Combined Blockade of TIGIT and CD39 or A2AR Enhances NK-92 Cell-Mediated Cytotoxicity in AML
Franziska Brauneck, Elisa Seubert, Jasmin Wellbrock, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 23, pp. 12919-12919
Open Access | Times Cited: 41
Page 1 - Next Page

Scroll to top